Oral contraception and thrombophilia

Current Opinion in Obstetrics and Gynecology

Volumn 19, Issue 4, 2007, Pages 370-376

  Blickstein, Dorit ^a,b   Blickstein, Isaac ^c,d  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c KAPLAN MEDICAL CENTER   (Israel)

^d HEBREW UNIVERSITY   (Israel)

Author keywords

Oral contraception; Thrombophilia; Venous thromboembolism

Indexed keywords

DESOGESTREL; ETHINYLESTRADIOL; LEVONORGESTREL;

ARTERY THROMBOSIS; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONFIDENCE INTERVAL; HUMAN; ORAL CONTRACEPTION; PHYSICIAN; PRIORITY JOURNAL; REVIEW; SCREENING; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

BLOOD COAGULATION TESTS; CONTRACEPTIVES, ORAL, HORMONAL; CONTRACEPTIVES, ORAL, SYNTHETIC; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MASS SCREENING; RISK ASSESSMENT; RISK FACTORS; THROMBOPHILIA; THROMBOSIS;

EID: 34447573783     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e32821642e6     Document Type: Review

References (30)

1. Jordan WM. Pulmonary embolism. Lancet 1961; ii:1146-1147.
2. Lorentz I. Parietal lesions and enavid. BMJ 1962; ii:1191.
3. Boyce J, Fawcett JW, Noall EWP. Coronary thrombosis and conovid. Lancet 1963; 1:111.
4. Blickstein I. Thrombophilia and women's health: an overview. Obstet Gynecol Clin North Am 2006; 33:347-356.
5. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344:1453-1457.
6. Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000; 321:1190-1195.
7. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000; 160: 49-52.
8. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346:1133-1134.
9. Farmer RD, Lawrenson RA, Thompson CR, et al. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349:83-88.
10. Rosendaal FR, Van Hylckama Vlieg A, Tanis BC, Helmerhorst FM. Estrogens, progestogens and thrombosis. J Thromb Haemost 2003; 1:1371-1380.
11. Rosing J. Oral contraceptives, thrombosis and haemostasis. Eur J Obstet Gynecol Reprod Biol 2001; 95:193-197.
12. Tans G. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000; 84:15-21.
13. Spitzer WO, Lewis MA, Heinemann LA, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996; 312:83-88.
14. Kemmeren JM. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001; 323:131-139.
15. Hennessy S, Berlin JA, Kinman JL, et al. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis. Contraception 2001; 64:125-133.
16. Kemmeren JM, Algra A, Meijers JC, et al. Effect of second- and thirdgeneration oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial. Blood 2004; 103:927-933.
17. Public Citizen Petition to the FDA to ban third generation oral contraceptives containing desogestrel due to increased risk of venous thrombosis (HRG publication #1799). 6 February 2007. Available at: http://www.citizen.org/ publications/release.cfm?ID=7503 Accessed: April 2007.
18. Kemmeren JM, Algra A, Meijers JC, et al. Effect of second- and thirdgeneration oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation. Blood Coagul Fibrinolysis 2002; 13:373-381.
19. Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344:1527-1535.
20. Tanis BC, van den Bosch MA, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001; 345:1787-1793.
21. Kemmeren JM, Tanis BC, van den Bosch MA, et al. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke 2002; 33:1202-1208.
22. Van den Bosch MA, Kemmeren JM, Tanis BC, et al. The RATIO study: oral contraceptives and the risk of peripheral arterial disease in young women. J Thromb Haemost 2003; 1:439-444.
23. Martinelli I, Sacchi E, Landi G, et al. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998; 338:1793-1797.
24. Wu O, Robertson L, Twaddle S, et al., The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol 2005; 131:80-90.
25. Blickstein D. Screening for thrombophilia. Obstet Gynecol Clin North Am 2006; 33:389-395.
26. Middeldorp S, Meinardi JR, Koopman MM, et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med 2001; 135:322-327.
27. Simioni P, Tormene D, Prandoni P, et al. Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood 2002; 99:1938-1942.
28. Martinelli I. Pros and cons of thrombophilia testing: pros. J Thromb Haemost 2003; 1:410-411.
29. Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114:512-528.
30. Rosendaal FR. Oral contraceptives and screening for factor V Leiden. Thromb Haemost 1996; 75:524-525.